Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Valerius

Showing results (41-50 of 106) with videos related to

Pageof 11
Sort By:
Frontiers in Immunology|April 30, 2019
Potent Fc Receptor Signaling by IgA Leads to Superior Killing of Cancer Cells by Neutrophils Compared to IgGArianne M Brandsma, Sina Bondza, Mitchell Evers, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 23, 2023
Bispecific Complement Engagers for Targeted Complement ActivationDennis V Pedersen, Heidi Gytz, Mikael B L Winkler, et al.
Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur Transfusionsmedizin Und Immunhamatologie|October 27, 2017
An Fc Double-Engineered CD20 Antibody with Enhanced Ability to Trigger Complement-Dependent Cytotoxicity and Antibody-Dependent Cell-Mediated CytotoxicityTim Wirt, Sophia Rosskopf, Thies Rösner, et al.
Journal for Immunotherapy of Cancer|October 30, 2021
Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastomaMitchell Evers, Marjolein Stip, Kaylee Keller, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 16, 2012
Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicityChristian Kellner, Tina Maurer, Daniela Hallack, et al.
British Journal of Haematology|April 3, 2004
A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective lysis of lymphoma cellsJoerg Bruenke, Barbara Fischer, Karin Barbin, et al.
Mabs|February 5, 2014
Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2m(1) antibodyChristina Brunke, Stefan Lohse, Stefanie Derer, et al.
Molecular Cancer Therapeutics|October 5, 2018
Immune Effector Functions of Human IgG2 Antibodies against EGFRThies Rösner, Steffen Kahle, Francesca Montenegro, et al.
Journal of Clinical Medicine|July 2, 2021
Engineering of CD19 Antibodies: A CD19-TRAIL Fusion Construct Specifically Induces Apoptosis in B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Cells In VivoDorothee Winterberg, Lennart Lenk, Maren Oßwald, et al.
The Journal of Biological Chemistry|June 9, 2012
Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophagesStefan Lohse, Christina Brunke, Stefanie Derer, et al.
Pageof 11

Showing results (41-50 of 106) with videos related to

Sort By:
Pageof 11
Frontiers in Immunology|April 30, 2019
Potent Fc Receptor Signaling by IgA Leads to Superior Killing of Cancer Cells by Neutrophils Compared to IgGArianne M Brandsma, Sina Bondza, Mitchell Evers, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 23, 2023
Bispecific Complement Engagers for Targeted Complement ActivationDennis V Pedersen, Heidi Gytz, Mikael B L Winkler, et al.
Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur Transfusionsmedizin Und Immunhamatologie|October 27, 2017
An Fc Double-Engineered CD20 Antibody with Enhanced Ability to Trigger Complement-Dependent Cytotoxicity and Antibody-Dependent Cell-Mediated CytotoxicityTim Wirt, Sophia Rosskopf, Thies Rösner, et al.
Journal for Immunotherapy of Cancer|October 30, 2021
Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastomaMitchell Evers, Marjolein Stip, Kaylee Keller, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 16, 2012
Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicityChristian Kellner, Tina Maurer, Daniela Hallack, et al.
British Journal of Haematology|April 3, 2004
A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective lysis of lymphoma cellsJoerg Bruenke, Barbara Fischer, Karin Barbin, et al.
Mabs|February 5, 2014
Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2m(1) antibodyChristina Brunke, Stefan Lohse, Stefanie Derer, et al.
Molecular Cancer Therapeutics|October 5, 2018
Immune Effector Functions of Human IgG2 Antibodies against EGFRThies Rösner, Steffen Kahle, Francesca Montenegro, et al.
Journal of Clinical Medicine|July 2, 2021
Engineering of CD19 Antibodies: A CD19-TRAIL Fusion Construct Specifically Induces Apoptosis in B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Cells In VivoDorothee Winterberg, Lennart Lenk, Maren Oßwald, et al.
The Journal of Biological Chemistry|June 9, 2012
Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophagesStefan Lohse, Christina Brunke, Stefanie Derer, et al.
Pageof 11